Associate Scientist, Biology
Lycia Therapeutics
Summary
Lycia Therapeutics is seeking an experienced, team-oriented, Associate Scientist with a strong biochemistry or biophysics background to help evaluate novel protein-based therapeutics. The candidate will work closely with members of the Biology and Biologics groups as part of an innovative research organization to advance LYTACs to the clinic.
Job description
Key Responsibilities
- Subject matter expert within project teams to help advance pipeline projects, prioritize new targets and meet corporate goals
- Generate high quality, reproducible data to support antibody discovery and engineering campaigns, characterize potential drug candidates, and enable further development of the LYTAC platform
- Assess receptor and target binding using a combination of plate-based fluorescence techniques and biophysical methods
- Design, develop and execute SPR and BLI workflows to prioritize antibodies for advancement based on binding affinities, kinetics and selectivity
- Conduct bioanalytical assays, ELISA/MSD, to evaluate LYTAC activity
- Evaluate, interpret, and document scientific results and communicate findings to project teams and leadership
Requirements
- B.S./M.S. in biophysics, biochemistry, or related field with 6-8 years of relevant post-graduate industry experience. A strong background in SPR or BLI assay development and workflows is required.
- Proficiency developing and conducting fluorescence-based assays to evaluate ligand binding, enzymatic activity and protein-protein interactions
- Hands-on experience with biophysical techniques including SPR and BLI to monitor protein-protein and protein-ligand interactions
- Previous experience measuring protein levels, signaling and viability using plate-based assays
- Ability to work independently while contributing to an integrated team
- Adherence to tight timelines across multiple research projects and adapt to changing priorities
- Highly motivated team player with excellent written and oral communication skills
- Flexibility to contribute to multiple projects while remaining well organized
- Creative problem solver with the demonstrated ability to overcome technical challenges
Requirements
- B.S./M.S. in biophysics, biochemistry, or related field
- 6-8 years of relevant post-graduate industry experience
- Strong background in SPR or BLI assay development and workflows
- Proficiency developing and conducting fluorescence-based assays to evaluate ligand binding, enzymatic activity and protein-protein interactions
- Hands-on experience with biophysical techniques including SPR and BLI to monitor protein-protein and protein-ligand interactions
- Previous experience measuring protein levels, signaling and viability using plate-based assays
- Ability to work independently while contributing to an integrated team
- Adherence to tight timelines across multiple research projects and adapt to changing priorities
- Highly motivated team player with excellent written and oral communication skills
- Flexibility to contribute to multiple projects while remaining well organized
- Creative problem solver with the demonstrated ability to overcome technical challenges
Benefits
- Annual performance bonus
- Equity
- Benefits program
Company overview
Lycia Therapeutics is a biotechnology company pioneering a novel approach to treating previously undruggable diseases through extracellular protein degradation. Founded in 2020 and headquartered in South San Francisco, California, the company is developing innovative LYTAC (Lysosome-Targeting Chimera) therapeutics designed to bind and eliminate disease-causing extracellular proteins by directing them into cells for degradation via the lysosome. The company's platform technology specifically targets proteins outside the cell, addressing a significant gap in current therapeutic approaches. Lycia initially focuses on autoimmune and inflammatory diseases, with lead programs targeting conditions like allergic asthma, chronic urticaria, and Graves' disease. The company has raised substantial funding, including a $106.6 million Series C round in 2024, demonstrating strong investor confidence in their technology platform. Lycia's modular therapeutics can be customized for various pathogenic proteins, offering new hope for patients with limited treatment options.